Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
Bristol Myers Squibb and Merck & Co hail front-line successes, but histology and biomarker status will remain live issues for doctors.